Silyl modification of biologically active compounds. 13. Synthesis, cytotoxicity and antibacterial action of N‐methyl‐N‐(2‐triorganylsiloxyethyl)‐1,2,3,4‐tetrahydro(iso)quinolinium iodides

A series of N-methyl-N-(2-triorganylsiloxyethyl)-1,2,3,4-tetrahydro(iso)quinolinium iodides has been synthesized via dehydrocondensation reaction of N-(2-hydroxyethyl)-1,2,3,4-tetrahydroisoquinoline, N-(2-hydroxyethyl)-1,2,3,4-tetrahydroquinoline and 4,4-dimethyl-N-(2-hydroxyethyl)-4-sila-1,2,3,4-tetrahydroisoquinoline with trialkyl(aryl)hydrosilanes and subsequent alkylation, and characterized by 1H, 13C and 29Si NMR and mass spectroscopy. The biological activity data exhibited a marked enhancement of inhibitory activity against tumour cell lines and almost all the test bacterial/fungal strains in comparison with their 2-hydroxyethyl precursors. Cytotoxicity in the microgram range against HT-1080 (human fibrosarcoma) and MG-22A (mouse hepatoma) cancer cell lines was observed for most of compounds. Copyright © 2012 John Wiley & Sons, Ltd.

[1]  S. Burt,et al.  A broad spectrum anticancer nucleoside with selective toxicity against human colon cells in vitro. , 2011, Bioorganic & medicinal chemistry letters.

[2]  M. A. Christiansen,et al.  Preliminary SAR analysis of novel antiproliferative N(6),5'-bis-ureidoadenosine derivatives. , 2009, Bioorganic & medicinal chemistry letters.

[3]  J. Chern,et al.  Design, synthesis and evaluation of tetrahydroisoquinolines as new kinesin spindle protein inhibitors. , 2009, Chemical & pharmaceutical bulletin.

[4]  V. Belakhov,et al.  Synthesis and antifungal activity of N-trialkylsilyl derivatives of nystatin , 2008, Pharmaceutical Chemistry Journal.

[5]  Audrey Wanger.  Disk Diffusion Test and Gradient Methodologies , 2007 .

[6]  D. Abraham,et al.  Identification of a series of tetrahydroisoquinoline derivatives as potential therapeutic agents for breast cancer. , 2007, Bioorganic & medicinal chemistry letters.

[7]  E. Lukevics,,et al.  Tetrahydroquinoline and tetrahydroisoquinoline mixed ligand rhenium complexes with the SNS/S donor atom set , 2007 .

[8]  E. Lukevics,,et al.  Silyl modification of biologically active compounds. 12. Silyl group as true incentive to antitumour and antibacterial action of choline and colamine analogues , 2006 .

[9]  G. F. Ruda,et al.  Acyclic nucleoside analogues as inhibitors of Plasmodium falciparum dUTPase. , 2006, Journal of medicinal chemistry.

[10]  Wayne Vaccaro,et al.  Inhibitors of human mitotic kinesin Eg5: characterization of the 4-phenyl-tetrahydroisoquinoline lead series. , 2006, Bioorganic & medicinal chemistry letters.

[11]  E. De Clercq,et al.  Improving the antiviral efficacy and selectivity of HIV-1 reverse transcriptase inhibitor TSAO-T by the introduction of functional groups at the N-3 position. , 2005, Journal of medicinal chemistry.

[12]  T. Martín,et al.  The tert-butyl dimethyl silyl group as an enhancer of drug cytotoxicity against human tumor cells. , 2005, Bioorganic & medicinal chemistry letters.

[13]  E. Lukevics,,et al.  Silyl Modification of Biologically Active Compounds. 10. Lipid Type Organosilicon Derivatives of 8-Hydroxyquinoline and N-(2-Hydroxyethyl)-1,2,3,4-tetrahydro(sila, iso)quinolines , 2005 .

[14]  T. Burke,et al.  The effect of DB-67, a lipophilic camptothecin derivative, on topoisomerase I levels in non-small-cell lung cancer cells , 2004, Cancer Chemotherapy and Pharmacology.

[15]  E. Lukevics,,et al.  Silyl Modification of Biologically Active Compounds. 8. Trimethylsilyl Ethers of Hydroxyl-containing Thiazole Derivatives , 2002 .

[16]  Robin M. Williams,et al.  Chemistry and biology of the tetrahydroisoquinoline antitumor antibiotics. , 2002, Chemical reviews.

[17]  H. Pinedo,et al.  New highly lipophilic camptothecin BNP1350 is an effective drug in experimental human cancer , 2000, International journal of cancer.

[18]  A. Zablotskaya,et al.  Silyl modification of biologically active compounds 5. Hydrolytic stability and biological activity of the trialkylsilyl derivatives of some heterocyclic bases , 1998 .

[19]  E. Raymond,et al.  In vitro antitumor activity of the novel marine agent, ecteinascidin-743 (ET-743, NSC-648766) against human tumors explanted from patients. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  H. Malonne,et al.  DNA topoisomerase targeting drugs: mechanisms of action and perspectives. , 1997, Anti-cancer drugs.

[21]  J. Plowman,et al.  Synthesis, antitumor activity, and chemical properties of silaplatin and related platinum (II) and platinum (IV) complexes derived from beta-silyl amines. , 1995, Journal of medicinal chemistry.

[22]  D. Fast,et al.  Nitric oxide production by tumor targets in response to TNF: paradoxical correlation with susceptibility to TNF‐mediated cytotoxicity without direct involvement in the cytotoxic mechanism , 1992, Journal of leukocyte biology.

[23]  J. L. García,et al.  Structural requirements of choline derivatives for ‘conversion’ of pneumococcal amidase A new single‐step procedure for purification of this autolysin , 1988, FEBS letters.

[24]  G. Cragg,et al.  Antineoplastic agents, 120. Pancratium littorale. , 1986, Journal of natural products.

[25]  J. Millership,et al.  Prodrugs utilizing a reversible silyl linkage , 1986 .

[26]  K. Yokoyama,et al.  Saframycin S, a new saframycin group antibiotic. , 1981, Journal of pharmacobio-dynamics.